Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

CD79b-targeted antibody-drug conjugate

DRUG CLASS:

CD79b-targeted antibody-drug conjugate

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

polatuzumab vedotin-piiq (3)

polatuzumab vedotin-piiq (3)

›

No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	rituximab + polatuzumab vedotin-piiq Sensitive: A1 - Approval rituximab + polatuzumab vedotin-piiq Sensitive : A1	rituximab + polatuzumab vedotin-piiq Sensitive: A1 - Approval rituximab + polatuzumab vedotin-piiq Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	polatuzumab vedotin-piiq Sensitive: A1 - Approval polatuzumab vedotin-piiq Sensitive : A1	polatuzumab vedotin-piiq Sensitive: A1 - Approval polatuzumab vedotin-piiq Sensitive : A1
BCL2 positive	Diffuse Large B Cell Lymphoma	BCL2 positive	Diffuse Large B Cell Lymphoma	venetoclax + polatuzumab vedotin-piiq Sensitive: C3 – Early Trials venetoclax + polatuzumab vedotin-piiq Sensitive : C3	venetoclax + polatuzumab vedotin-piiq Sensitive: C3 – Early Trials venetoclax + polatuzumab vedotin-piiq Sensitive : C3
CD79B expression	T Cell Non-Hodgkin Lymphoma	CD79B expression	T Cell Non-Hodgkin Lymphoma	ARC-02 Sensitive: D – Preclinical ARC-02 Sensitive : D	ARC-02 Sensitive: D – Preclinical ARC-02 Sensitive : D